Exploring FLOT- and FOLFOX-Based total neoadjuvant therapy for patients with locally advanced gastroesophageal cancers

Abstract

Understanding the currently available evidence regarding multimodal approaches is critically important. The Southwest Oncology Group INT-0116 trial demonstrated improved overall survival and disease-free survival using adjuvant therapy-specifically CRT-compared to surgery alone [16]. Subsequently, several other studies have supported the use of postoperative chemotherapy and/or CRT in addition to surgery with improved outcomes [17][18][19][20][21]. This was followed by the MAGIC trial, which demonstrated a survival advantage for the use of perioperative combination chemotherapy (epirubicin, cisplatin,) as compared to resection alone and